MONMOUTH JUNCTION, N.J., Oct. 18, 2018 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that it will showcase CytoSorb at the 32nd European Association for CardioThoracic Surgery Conference (EACTS) in Milan, Italy from October 18-20, 2018, and the 31st European Society of Intensive Care Medicine Congress (ESICM) in Paris, France from October 20-24, 2018.

CytoSorbents Logo. (PRNewsFoto/CytoSorbents)

32nd European Association for CardioThoracic Surgery (EACTS) 2018
The EACTS conference is the largest cardiothoracic surgery meeting in the world, focused on communicating scientific developments and research in the field to more than 4,000 surgeons, perfusionists, and allied healthcare workers worldwide.

CytoSorbents is an exhibitor at EACTS 2018 and today will host a research symposium entitled “Update on the role of CytoSorb hemoadsorption in cardiac surgery patients“, chaired by Prof. Dr. med. Jan Gummert (Bad Oeynhausen, Germany) and Dr. Guillaume Lebreton (Paris, France).  Presentations include:

  • Multi-organ Failure in ECMO patients and the impact of CytoSorb therapy – 3 years’ experience
    Dr. Federico Pappalardo (Milan, Italy)
  • Clinical effects of intraoperative hemoadsorption in acute infective endocarditis – A case series
    Prof. Dr. med. Daniel Wendt (Essen, Germany)
  • Improved outcome of patients undergoing heart transplant with CytoSorb – Results from an observational study
    Dr. Endre Nemeth (Budapest, Hungary)
  • Intraoperative removal of Ticagrelor to reduce bleeding complications in emergency cardiac surgery Experiences from Hamburg
    Prof. Dr. med. Michael Schmoeckel (Hamburg, Germany)

In addition, at a separate session entitled, “Strategies to minimize end-organ damage from aortic surgery”, the following presentation will be given:

  • Haemimmunoadsorption Improves the Course of Anaesthesia for Aortic Surgery Under Deep Hypothermic Cardiac Arrest
    T. Saller, Munich, S. Woitsch, Munich, M. Luehr, Munich, F. Born, Munich, T. Kammerer, Munich, M. Pichlmaier, Munich, C. Hagl, Munich, P. Scheiermann (Munich, Germany)

European Society of Intensive Care Medicine Congress (ESICM)
The ESICM conference is one of the most important global critical care conferences that traditionally attracts more than 6,000 physicians, anesthetists, trainees, nursing, and allied health professionals worldwide.  CytoSorbents is a major conference sponsor and an exhibitor, and will exhibit there from October 20-24, 2018.

Notable sessions:

Monday, October 22, 2018
During the regular session entitled, “Perioperative cardiac intensive care”, the following presentation will be given:

  • The pros and cons of extracorporeal cytokine adsorption therapy
    Dr. med. Matthias Derwall (Aachen, Germany)

Tuesday, October 23, 2018, Poster Presentations:

  • Hemoadsorption by extracorporeal cytokine adsorption therapy (CytoSorb) in the management of sepsis: a retrospective observational study
    YP Singh (New Dehli, India)
  • Cytokine and DAMP adsorption in septic AKI
    CM Laubach (Munich, Germany)

Tuesday, October 23, 2018,  CytoSorb Satellite Symposium
CytoSorb Therapy: Therapeutic options and current evidence
Chair: Dr. Marlies Ostermann (London, England)

  • Treatment in early septic shock
    Dr. Zsolt Molnar (Szeged, Hungary)
  • Combination of ECMO and CytoSorb therapy extends your therapeutic options
    Prof. Dr. med. D Duerschmeid (Freiburg, Germany)
  • Liver toxin removal AND impact on inflammation to enhance clinical effects
    Dr. A de Gasperi (Milan, Italy)
  • Personal experience (off label use): A new therapeutic tool in various severe intoxications
    Dr. Patrick Honore (Brussels, Belgium)

About CytoSorbents Corporation (NASDAQ: CTSO)

CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 53 countries around the world, as an extracorporeal cytokine adsorber designed to reduce the “cytokine storm” or “cytokine release syndrome” that could otherwise cause massive inflammation, organ failure and death in common critical illnesses. These are conditions where the risk of death is extremely high, yet no effective treatments exist.  CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators that can lead to post-operative complications, including multiple organ failure. CytoSorbents is conducting its pivotal REFRESH 2-AKI trial – a multi-center, randomized controlled, clinical trial intended to support U.S. regulatory approval of CytoSorb for use in a heart-lung machine during complex cardiac surgery to reduce organ injury.  CytoSorb® has been used in more than 46,000 human treatments to date.

CytoSorbents’ purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of approximately $25 million from DARPA, the U.S. Army, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (USSOCOM), and others. The Company has numerous products under development based upon this unique patented blood purification technology including CytoSorb-XL™, HemoDefend™, VetResQ™, K+ontrol™, ContrastSorb, DrugSorb, and others.  For more information, please visit the Company’s websites at and or follow us on Facebook and Twitter.

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 8, 2018, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.

CytoSorbents Contact:
Amy Vogel
Investor Relations
[email protected]

Investor Relations Contact:
Jeremy Feffer
LifeSci Advisors
[email protected]

Public Relations Contact:
Joshua Berkman
Rubenstein Public Relations
[email protected]

SOURCE CytoSorbents Corporation